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The PTEN tumor suppressor is frequently af-
fected in cancer cells, and inherited PTEN mu-
tation causes cancer-susceptibility conditions
such as Cowden syndrome. PTEN acts as a
plasma-membrane lipid-phosphatase antago-
nizing the phosphoinositide 3-kinase/AKT cell
survival pathway. However, PTEN is also found
in cell nuclei, but mechanism, function, and rel-
evance of nuclear localization remain unclear.
We show that nuclear PTEN is essential for tu-
mor suppression and that PTEN nuclear import
is mediated by its monoubiquitination. A lysine
mutant of PTEN, K289E associated with Cow-
den syndrome, retains catalytic activity but fails
to accumulate in nuclei of patient tissue due to
an import defect. We identify this and another
lysine residueasmajormonoubiquitinationsites
essential for PTEN import. While nuclear PTEN
is stable, polyubiquitination leads to its degra-
dation in the cytoplasm. Thus, we identify can-
cer-associated mutations of PTEN that target
its posttranslational modification and demon-
strate how a discrete molecular mechanism
dictates tumor progression by differentiating
between degradation and protection of PTEN.
INTRODUCTION
Since the original identification of the tumor suppressor
phosphatase and tensin homolog on chromosome TEN(PTEN) (Li et al., 1997; Steck et al., 1997), numerous re-
ports have described PTEN loss or mutation in cancer
specimens, cancer cell lines, and inherited cancer predis-
posing syndromes (Bonneau and Longy, 2000; Li et al.,
1997), rendering this gene one of the most frequently af-
fected tumor suppressors of the post-p53 era.
To better understand the causal nature of PTEN loss in
human cancer, we and others have genetically modeled
the effects of Pten loss in mice and have shown that such
animals faithfully recapitulate the tumor spectrum ob-
served in PTEN-deficient patients (Di Cristofano et al.,
1998; Podsypanina et al., 1999; Suzuki et al., 1998;
Trotman et al., 2003). These studies have firmly linked
Pten loss to the stage of tumor initiation in epithelial can-
cer. Most notably, we have demonstrated PTEN haploin-
sufficiency (reviewed in Sherr [2004]), as a single copy be-
comes unable to prevent prostate cancer either in the
context of loss of certain other tumor suppressor genes
(Di Cristofano et al., 2001; Ma et al., 2005; Trotman
et al., 2006) or, alternatively, in the context of genetically
engineered reduction of Pten expression just below het-
erozygosity (Trotman et al., 2003). In addition, we have
shown recently that complete Pten loss even provokes
the p53-dependent cellular senescence response (Chen
et al., 2005) that antagonizes prostate tumorigenesis, re-
defining the previously assumed interplay of these two
major tumor suppressor genes (Trotman and Pandolfi,
2003). This finding further underscored the importance
of a ‘‘non-Knudsonian’’ single-hit working model for loss
of PTEN in tumor initiation and clarifies why indeed a ma-
jority of human tumors are retaining a wild-type (WT) copy
of PTEN (Sansal and Sellers, 2004). Thus, understanding
the mechanisms of PTEN regulation that govern this ‘‘het-
erozygous tumor progression’’ is imperative for progress
in the field.Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc. 141
PTEN catalyzes the conversion of the membrane lipid
second messenger PIP3 to PIP2 (Maehama and Dixon,
1998) and therefore is the key antagonist of various PIP3-
dependent proto-oncogenic kinases, chiefly among them
AKT/PKB (Stambolic et al., 1998). This firmly links PTEN
action to the cell’s plasma membrane (Cantley, 2002; Di
Cristofano and Pandolfi, 2000). However, it has long been
observed that in several tissues and cultured cells PTEN is
also found in cell nuclei (reviewed in Lian and Di Cristofano
[2005]). While it remains unclear what function can be at-
tributed to this nuclear pool of PTEN specifically, positive
correlation between nuclear PTEN and suppression of tu-
mor progression has been described for both cutaneous
melanoma and colorectal cancer (Whiteman et al., 2002;
Zhou et al., 2002). But in spite of such correlative studies,
to date no proof for an essential role of nuclear PTEN in
tumor suppression has been accrued. Furthermore, al-
though these data suggested that nuclear PTEN could
retain some activity, it still has remained unclear how
PTEN subcellular localization would be regulated.
Nuclear protein import is generally mediated by distinct
and, importantly, transferable nuclear localization signal
(NLS) sequences such as the SV-40 T-antigen-like cluster
of positively charged amino acids. Such sequences confer
binding to import receptors, whichmediate uni- or bidirec-
tional transport across the nuclear pore complexes
(NPCs; see Chook and Blobel [2001] and Gorlich and Ku-
tay [1999]). Yet no functional NLS sequence satisfying the
essential criteria has been found in PTEN, suggesting that
PTEN either binds to another NLS-bearing protein to be
transported in a ‘‘piggyback’’ fashion or that an altogether
novel mechanism could regulate its nuclear import.
We describe here the discovery of a cancer-associated
mutation that targets PTEN posttranslational modification
and leads to an aberrant nuclear exclusion phenotype in
a family of patients with Cowden syndrome (CS). CS is
one of three closely related autosomal dominant cancer
syndromes caused by germline-inactivating mutations of
PTEN and is characterized by high cancer susceptibility
(Eng, 2003). By identifying the biophysical, biochemical,
and cell-biological deficiencies of this mutant, we here es-
tablish a causal relationship between PTEN posttransla-
tional modification, nuclear import, and tumor initiation.
RESULTS
Nuclear Exclusion of PTENK289E in Cowden Patient
Polyps
We have previously solved the PTEN crystal structure (Lee
et al., 1999), revealing an N-terminal phosphatase and
a C-terminal C2 domain that stabilizes the catalytic do-
main and is essential for proper positioning of PTEN at
the cell membrane (Georgescu et al., 2000 and see also
Figure 1C). While most known PTEN missense mutations
target the phosphatase domain, such as the catalytic cys-
teine 124 to arginine mutant (C124R, see abbreviations
[Nelen et al., 1997]), some disrupt PTEN function by indi-
rectly affecting catalytic domain architecture (Lee et al.,142 Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc.1999). Yet cancer-associated missense mutations have
also been identified in regions of no apparent relevance to
PTEN enzymatic function or stability. Prominent among
them is a mutation found in a stretch of 32 amino acids
within theC2domain,whichwe term theC2 loop. This loop
of PTEN is highly conserved among vertebrates, including
zebrafish (Figure 1A). As previously described, the C2 loop
(similar to N- and C-terminal tails of PTEN) interferes with
proper crystal formation (Figure 1B) and can be specifically
digestedby subtilisin, consistentwitha randomandacces-
sible conformationprotruding fromthe frameworkof theC2
domain (Figure 1C). Importantly, C2 loop-deficient PTEN
retains WT activity in vitro and in vivo (Lee et al., 1999).
Yet, intriguingly, a missense mutation targeting a con-
served residue of the C2 loop, K289E, has been described
(see Figure 1A). In agreement with the above observations,
PTENK289E displays no significant defects in activity or
membrane association (Georgescu et al., 2000), as K289
faces away from the plasma membrane (Figure 1C).
Thus, taken together, theC2 loop has no positive structural
function, its lossdoesnot impingeonPTENactivity, and the
C2 loopK289Emutant retains its enzymatic activity in vivo.
Yet theK289E allele ofPTEN is found inherited in a family in
which carriers with one mutant allele display CS (Chi et al.,
1998), thus demonstrating genetically that the K289E
mutant is indeed defective in tumor suppression.
To investigate the paradox of how an enzymatically
functional PTENmutant can cause CS, we sought to study
tumor samples of a family member who inherited the
K289E mutation. Since these patients routinely undergo
colonoscopy for removal of intestinal polyps, we analyzed
this tissue (Figure 1D). Dysplastic intestinal polyps have
large areas of poorly differentiated glandular structures
at their surface (red rectangle, top), and this polyp’s stalk
featured also a small area of normal colonic mucosa
(green rectangle, top). As previously shown (Chi et al.,
1998), the bulk of these polyps lose the WT PTEN allele
while retaining the mutant and thus are expressing only
the PTENK289E protein that we sought to study by immu-
nohistochemistry. As depicted, the dysplastic surface
area retains PTEN expression (consistent with loss of the
WT PTEN copy and demonstrating PTENK289E stability),
yet magnification reveals that, surprisingly, PTEN is ex-
cluded from cell nuclei of epithelial cells (Figure 1D, right
panel series). Remarkably, interstitial lymphocytes, which
retain bothWT andK289Emutant protein (Chi et al., 1998),
in contrast also retain nuclear PTEN staining, serving as
internal control for the staining procedure (right and left
panel series, lowest panels, ly versus ep). Intriguingly, ep-
ithelial cells in the normal areas of the polyp’s stalk, areas
that typically retain both mutant and WT PTEN copies,
display strong nuclear and cytoplasmic PTEN staining
(left panel series), very similar to interstitial lymphocytes
(high magnification, lowest panel). Identical results were
obtained when using two different antibodies for staining
(see Experimental Procedures). Thus, the K289E mutant
protein appears to display an aberrant subcellular locali-
zation, reminiscent of a nuclear exclusion phenotype.
Figure 1. The PTENK289E Cowden Mutant Shows Nuclear Exclusion in Patient Samples
(A) Sequence alignment of the PTEN C2 loop (blue bar) from various species shows K289 conservation in vertebrates (highlighted in red).
(B) PTEN cleavage requirements for crystallization reveal that the C2 loop does not contribute to structural integrity (K denotes K289).
(C) Localization and size of the C2 loop within the PTEN structure (single amino acid code over backbone). Note that the C2 loop faces away from the
cell membrane (top) and membrane-interacting loops of the C2 domain (gray dots).
(D) Intestinal polyp from a PTENwt/K289E Cowden patient shows nuclear and cytoplasmic PTEN in normal (PTENwt/K289E) mucosa (left panel magnifi-
cation series, green) and only cytoplasmic PTENK289E in dysplastic (PTEND/K289E) regions (right panel magnification series, red). ‘‘ly’’ denotes circu-
lating lymphocytes (PTENwt/K289E), and ‘‘ep’’ denotes epithelial cells.Intrinsic Nuclear Import Defect of PTENK289E
Since the above-shown mislocalization could be either an
intrinsic property of theK289Emutation or apolyp-specific
effect on PTENK289E, we analyzed themutants’ subcellular
distribution in vitro. By immunofluorescence (IF), endoge-nous PTEN is found in both cell nuclei and cytoplasm of
most common human and murine cell lines and primary
murine cells (data not shown), similar to the localization
shown in the PTEN heterozygous prostate cancer cell
line DU-145 (Figure 2A). To test mutant PTEN localization,Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc. 143
Figure 2. The PTENK289E Cowden Mutant Has an Intrinsic Nuclear Import Defect
(A) IF of endogenous PTEN in prostate cancer-derived PTEN+/ DU-145 cells. Scale bar, 10 mm.
(B) Localization of GFP-PTEN fusions reveals nuclear exclusion of the K289E mutant at 12 hr posttransfection. Scale bars, 10 mm.
(C) FRAP analysis of WT and PTENK289E shows nuclear accumulation after nuclear photobleaching. Error bars show standard deviation (SD).
(D) Quantification of (C) and quantification of nuclear export FRAP results for WT and mutant proteins. Error bars show SD.PTEN-deficient prostate cancer cells (PC3) were tran-
siently transfected. When overexpressed as GFP fusion,
WT PTEN efficiently equilibrated between nucleus and cy-
toplasm within 10–12 hr after transfection (Figure 2B). Of
note, PTEN localization was unaffected by catalytic activ-
ity, as revealed by the distribution of the enzyme-dead
PTENC124S mutant (lower left panel), demonstrating that
AKT activity (which is high in PC3 cells and only lowered
upon WT PTEN transfection) does not visibly affect PTEN
localization. Strikingly, at this time point the PTENK289E
mutant showed dominant cytoplasmic accumulation in
most cells, which is also unaffected by loss of enzymatic
activity in the PTENK289E, C124S double mutant (Figure 2B,
right). The same results were obtained by visualizing
non GFP-tagged PTEN and the corresponding mutants
(Figure S1A, top). Notably, nuclear staining of the K289E144 Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc.mutant was found to increase by 24 and 48 hr after trans-
fection (data not shown). Since steady-state cytoplasmic
accumulation can in principle result from reduced nuclear
import or enhanced nuclear export of PTENK289E (indica-
tive of a loss- or gain-of-function mutation, respectively),
we next tested the nuclear and cytoplasmic accumulation
rates of the PTEN mutant quantitatively. The fluorescence
recovery after photo bleaching (FRAP) technique pro-
duces distinguishable (yet chemically identical) cytoplas-
mic and nuclear PTEN populations by bleaching GFP fluo-
rescence in either the cell nucleus or cytoplasm. Then the
compartmental equilibration, which occurs via nuclear
import andexport, canbemeasuredby time-lapse fluores-
cence microscopy (see Experimental Procedures).
We found that WT PTEN fluorescence reaccumulated
inside the nucleus, reaching equilibrium by roughly 15
min post-nuclear bleaching (Figure 2C). The PTENK289E
mutant, in contrast, showed clearly reduced nuclear accu-
mulation and no equilibration within the same time. Calcu-
lation of the nuclear accumulation rates (i.e., apparent nu-
clear import rates) revealed an 18-fold reduction in nuclear
net import for the K289E mutation (Figure 2D). Notably,
dynamic analysis revealed that even when steady-state
nuclear levels ofWT andmutant PTEN appear to be similar
(by static analysis), the mutant still shows a strongly
reduced rate of nuclear accumulation. Importantly, the
apparent export rate of the mutant protein was also de-
creased (Figure 2D), excluding a gain-of-export function
through the K289E mutation. This result also excludes
the possibility that WT nuclear localization is due to nu-
clear retention via K289 (which would result in higher
K289E export rates). To exclude charge-conversion
effects associated with the K289E mutation, the K289R
mutant was measured and also revealed PTEN import
deficiency (Figure S1B). Also of note, intranuclear and
intracytoplasmic diffusion coefficients (as measured by
FRAP) were not affected by the mutation (data not shown,
see Experimental Procedures). Therefore, taken together,
our experiments revealed that PTENK289E has a nuclear
import/export defect and thus represents a loss-of-func-
tion mutant, defective in nucleocytoplasmic shuttling.
Lysine 289 Is a Major Site for PTEN Ubiquitination
Given its exposure and accessibility, we sought to deter-
mine whether lysine 289 (K289) represented a PTEN ubiq-
uitination site. Ubiquitination is catalyzed by the sequential
action of an E1 enzyme that transfers activated ubiquitin
(Ub) to an E2 ligase. This, in concert with an E3 ligase, me-
diates ubiquitination of target proteins, usually on several
variable target lysines, thus defining a system of utmost
importance to cancer biology (Hershko and Ciechanover,
1998; Hoeller et al., 2006). We have identified NEDD4-1 as
the major E3 Ub ligase of PTEN (Wang et al., 2007 [this is-
sue of Cell]) and therefore tested whether NEDD4-1 ubiq-
uitinates K289 in an in vitro assay. We used purified PTEN
as a substrate and lysine-free Ub (KØ-Ub) to prevent poly-
Ub chain formation and promote ubiquitination of all avail-
able sites on PTEN, visible as discrete bands in PTEN
western blotting. As shown in Figure 3A (left lanes, WT), in-
cubation of PTEN with the E2 ligase alone showed three
specific adducts, likely representing single-, dual-, and tri-
ple-monoubiquitinated forms of PTEN, while addition of
NEDD4-1 revealed at least seven discrete adduct forms
of PTEN, consistent with the role of NEDD4-1 as E3 ligase.
When carrying out this assay with the purified PTENK289E
mutant, we found that at least one adduct band wasmiss-
ing, strongly suggesting that K289 is a target lysine for
PTEN ubiquitination (Figure 3A, right lanes, K289E).
Since lack of ubiquitination in this system could also be
due to an indirect effect of themutation, we sought to con-
firm K289 ubiquitination directly by mass spectrometry
(MS). However, our attempts at identifying even the un-
modified tryptic fragment containing the K289 residue by
MS failed because the tryptic loop fragment was too largeto be retrieved in sample preparation (see Experimental
Procedures). Therefore, we engineered two tryptic target
sites flanking K289 into the C2 loop to produce PTENRKR
(Figure 3B, top), which was indistinguishable from WT
PTEN regarding enzymatic activity (see Figure S1C in
the Supplemental Data available with this article online).
GST-fused PTENRKR was ubiquitinated in vitro, enriched,
and purified by GST pull-down, and, after SDS-PAGE/
Coomassie staining, the fast migrating unmodified
PTENRKR (below referred to as PTEN) and the first shifted
band (termed +1) were both excised and processed for
MS analysis. As intended, two expected tryptic fragments
of the C2 loop (see Figure 3B, middle, fragments ‘‘I’’ and
‘‘II’’) were now clearly detectable by analysis of the
PTEN band, demonstrating that the main PTEN Coomas-
sie band contained only the unmodified C2 loop
(Figure 3C, see upper panels for masses and lower panels
for MS spectra). Analysis of the +1 band, in contrast, re-
vealed a higher mass peptide of 1507.70 Da, as predicted
for the loop peptide linked by branching to two additional
glycine residues, the leftover of a Ub adduct after tryptic
digestion (Figure 3C, PTEN-Ub, and Figure 3B, lowest
panel). Thus, K289 is a target lysine for PTEN ubiquitina-
tion, coherent with its structural exposure in the C2 loop.
A Second, N-Terminal Ubiquitination Site Is Mutated
in Cancer and Regulates PTEN Import
To test for the presence of Ub adducts on PTEN residues
in cells, samples obtained from PTEN overexpression/
immunoprecipitation (IP) in PC3 cells were processed
for MS, which resulted in the identification of another Ub-
adduct site, PTEN K13 (see Experimental Procedures).
The molecular weight of the tryptic T peptide including
K13 was measured at 956.579 Da (Figure 3D). Similar to
the internal C2 loop, the N-terminal 13 residues of PTEN
are also unstructured and exposed (Lee et al., 1999) and
thus form targets for posttranslational modification. Strik-
ingly, K13 of PTEN is also found mutated to glutamic acid
(K13E) in spontaneous cancer (Duerr et al., 1998). To test
whether this mutation also affects PTEN shuttling, we an-
alyzed its localization. As shown in Figure 3E, PTENK13E
was enriched in the cytoplasm and FRAP analysis
revealed a defect in nuclear import as well as export (Fig-
ure 3F, data not shown). Notably, as shown in Figure S1D,
K13 is also highly conserved.
Since K13 is part of a positively charged cluster
(RNKRR), which could potentially function as an SV-40-
type NLS for PTEN, the K13E mutation could simply be
disrupting a basic NLS by replacing a positive charge
with the negative charge of glutamic acid. We therefore
tested whether the charge-conserving but ubiquitina-
tion-abolishing K13R mutation could still impeach import.
Also, this mutant displayed strong cytoplasmic accumula-
tion due to a nuclear import defect (Figures 3E and 3F,
K13R), demonstrating that the positively charged patch
does not function as PTEN-specific NLS but instead that
the presence of the lysine residue is required, consistent
with requirement for its ubiquitination to regulate import.Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc. 145
Figure 3. K13 and K289 Are Major Sites of PTEN Ubiquitination
(A) In vitro PTEN monoubiquitination assays using NEDD4-1 E3 ligase (ND4-1) reveal several target sites in WT PTEN and loss of at least one corre-
sponding target site(s) (‘‘+7/6b’’) in the K289Emutant (red). Note that numbering reflects only an estimate of the true adduct number. Asterisks denote
non-Ub-specific aggregates. Molecular weights in kDa.
(B) (Top) Location of engineered tryptic sites for MS identification in PTENRKR. (Middle) The two expected tryptic C2 loop fragments for PTENRKR
(I and II). (Bottom) Expected fragment for K289-ubiquitinated PTENRKR (red).
(C) MS of PTENRKR and the first adduct band reveals the expected fragments for unmodified PTEN and PTEN ubiquitinated at K289 (top, red). Lower
panels show spectra of unmodified and modified PTEN with masses. ‘‘C¸’’ denotes cysteine-acryl-amide (see Experimental Procedures).146 Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc.
Our experiments with the K13E, K289E double mutant
revealed that the two lysine residues can cooperate in pro-
moting PTEN import (Figure 3F, K13E, K289), consistent
with the notion that they are part of the limited set of Ub
target lysines of PTEN (revealed in Figure 3A).
Taken together, we have identified two lysine residues
that function as ubiquitination sites, are essential for
PTEN shuttling and import, and are implicated in heredi-
tary (K289E) and spontaneous (K13E) cancer.
PTEN Ubiquitination In Vivo
Next, we asked to what extent PTEN ubiquitination was
occurring in vivo. While endogenous PTEN is efficiently
mono- and polyubiquitinated upon overexpression of
His-tagged Ub (Wang et al., 2007), overexpressed PTEN
was found similarly ubiquitinated in cells: western blot
analysis of lysates stained for PTEN revealed the appear-
ance of two PTEN-specific slower migrating bands
(Figure 4A) that increased over time (using two different
antibodies, see Experimental Procedures). In addition,
a smear was seen at later time points, as expected for pol-
yubiquitination. The discrete bands comigrated with vari-
ous tagged forms of PTEN, as expected for covalently
linked adducts (Figure 4B, see also Figure S1E for lower
exposure). To test whether these adducts were indeed
formed by Ub, we coexpressed both KØ-Ub and WT Ub
plasmids together with GFP-PTEN followed by IP. As
shown, overexpression of PTEN and KØ-Ub resulted in
several discrete mono-Ub adducts, bands that were
even more prominent upon coexpression of unmodified
Ub (Figure 4C, left, 1–3) due to the nature of that plasmid
(see Experimental Procedures, Figure 5C, and Figure S1F
for expression efficiencies and levels of the Ub plasmids).
Ub overexpression also prompted a strong nonresolvable
smear of polyubiquitinated PTEN (Figure 4C, left, poly).
Analyzed vis-a`-vis the PTEN input, the discrete bands co-
incided with the shifted bands of PTEN in a pattern similar
to the one shown above but revealing an additional adduct
(termed +1) (Figure 4C, right). Our results therefore
showed that, similar to endogenous PTEN (Wang et al.,
2007), overexpressed PTEN forms mono- as well as
poly-Ub adducts in cells.
Next, we sought to determine whether the lysine mu-
tants show a ubiquitination defect. To this end, we made
use of a GFP-PTEN-KØ-Ub (GFP-PTEN-Ub-KØ) fusion
protein (see Experimental Procedures). As shown in
Figure 4D, this PTEN construct is present at lower levels
in cells due to massive ubiquitination (for unknown rea-
sons) resulting in its degradation, yet it does not appear
to affect general ubiquitination (right). This tool allowed
us to study PTEN ubiquitination directly by enhancing
ubiquitination of PTEN exclusively, in contrast to Ub over-
expression or proteasome inhibition, which enhances
ubiquitination of all cellular Ub target proteins.To test the contribution of K289 and K13 to PTEN ubiq-
uitination, cells were transfected with the GFP-PTEN-Ub-
KØ-K289E and GFP-PTEN-Ub-KØ-K13E mutants, re-
spectively. As shown (Figure 4E), the WT fusion protein
displayed a distinct mono-Ub band as well as a poly-Ub
smear (note molecular weights), which characteristically
extended into the stacking gel. Notably, the mono-Ub-
specific shift (Figure 4E, mono-Ub) was clearly reduced
in both the K13 and K289 mutants (see magnification
and quantification in Figure 4E, right), confirming the func-
tion of these lysines as important targets for PTEN mono-
ubiquitination in vivo. Note that forced Ub overexpression,
in contrast, always rescued PTEN mutant ubiquitination,
as expected given the number of possible target sites
(data not shown, see also Figures 5C and 5D, below).
Monoubiquitination Dictates PTEN Nuclear Import
Ub has previously been linked to protein transport (Li et al.,
2003; Lohrum et al., 2001; Massoumi et al., 2006; Plafker
et al., 2004), and we sought to determine whether it could
affect PTEN shuttling by FRAP. Ub coexpression resulted
in a significant acceleration of PTEN nuclear import (Fig-
ure 5A, left). Quantification revealed a >50% increase in
apparent import rates and export rates (Figure 5A, right),
suggesting that PTEN ubiquitination may enhance shut-
tling. Moreover, we found that the nuclear resident fraction
of PTEN was also increased upon Ub overexpression
(Figure 5B, compare PTEN and PTEN +Ub in nuclear frac-
tions). Notably, nuclear PTEN was not quantitatively
monoubiquitinated, suggesting that PTEN is deubiquiti-
nated to remain nuclear or else re-exported. In sum, our
results demonstrated that ubiquitination positively affects
PTEN shuttling, complementing the finding of reduced
ubiquitination and transport of the PTEN mutants.
To test whether the nuclear import defect of the K289E
mutant could be overcome by forced ubiquitination, we
coexpressed PTENK289E with Ub and assessed PTEN lo-
calization by IF at 12 hr posttransfection. As shown in
Figure 5C, PTENK289E was enriched in the cytoplasmwhile
WT PTEN had equilibrated into the nucleus at this time
point. Ub coexpression, in contrast, resulted in nuclear ac-
cumulation of the PTENK289E mutant (Figure 5C, K289E +
Ub). Because the Ub plasmid promotes both PTENmono-
and poly-Ub formation (see Figure 4C), we next tested
whether the KØ-Ub construct, which only supports mono-
ubiquitination, was also able to rescue import. Indeed,
cells cotransfected with the K289E mutant and KØ-Ub
displayed very clear nuclear PTENK289E staining, strongly
suggesting that mono-Ub suffices to rescue the import
defect. To confirm and quantify these results, we per-
formed rescue experiments using FRAP. Figure 5D shows
that coexpression of PTENK289E and the Ub plasmid
similarly enhanced the overall import of the mutant
(Figure 5D, left, K289E + Ub). But most importantly,(D) MS of immunoprecipitated PTEN after overexpression in cells reveals the peptide expected for a tryptic Ub adduct on K13.
(E) IF staining of GFP-tagged K13 mutants. Scale bar, 10 mm.
(F) FRAP and quantification of the apparent import rates of mutants visualized in (E). Error bars show SD.Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc. 147
Figure 4. K13 and K289 Are Ubiquitinated In Vivo
(A) PTEN shows adduct formation in vivo and a smear (poly) at 36 hr posttransfection. Molecular weights in kDa. ‘‘n’’ denotes a nonspecific band, and
asterisks indicate migration of unmodified (single) and modified (double) PTEN.
(B) Discrete adducts comigrate with various PTEN fusions. Asterisks as in (A). Molecular weights in kDa.
(C) Immunoprecipitation of GFP-PTEN after HA-Ub coexpression confirms discrete mono- (labeled 1–3) and poly-Ub adducts (labeled poly). Migra-
tion of GFP-PTEN is shown. Molecular weights in kDa.
(D) Low steady-state levels (left), strong ubiquitination (middle), and PTEN-specific ubiquitination (right) of the GFP-PTEN-Ub-KØ fusion. Molecular
weights in kDa.
(E) Defects in monoubiquitination of the indicated lysine mutants. Left panel shows overview (location of stacking gel and molecular weights are
indicated), and right panels show magnification and quantification of ratios for mono-Ub:main PTEN band intensities.148 Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc.
Figure 5. Monoubiquitination Regulates PTEN Nuclear Import and Shuttling
(A) FRAP assay measuring effect of Ub overexpression on PTEN import (left) and quantification of nuclear and cytoplasmic PTEN accumulation rates
(right). Error bars show SD.
(B) Nuclear/cytoplasmic fractionation of PTEN after Ub overexpression. Lamin B1 and a-tubulin serve as nuclear and cytoplasmic markers, respec-
tively. Numbers denote nuclear to cytoplasmic PTEN ratios (relative to lamin and tubulin, see Supplemental Data). A non-PTEN-specific band is
indicated (n).
(C) IF imaging of PTEN and K289E with Ub coexpression. Scale bar, 10 mm.
(D) Ubiquitination rescues K289E nuclear import defect as measured by FRAP (left; quantifications, right). Note that monoubiquitination is most
efficient in rescuing. Error bars show SD.coexpression of the KØ-Ub mutant accelerated
PTENK289E import far more efficiently (K289E + KØ-Ub).
Quantification of this rescue series showed that while Ubreset the K289E defect to approximately WT PTEN import
levels, coexpression of KØ-Ub was 7-fold more powerful
(right, K289E + KØ-Ub).Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc. 149
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Next, we sought to determine whether endogenous
PTEN localization could be affected by lack of ubiquitina-
tion. To this end, we used the temperature-sensitive cell
line ts20, in which ubiquitination is strongly reduced due to
E1 ligase disruption at the restrictive temperature (Chow-
dary et al., 1994). As shown (Figure 6A), Pten localization
at the permissive temperature was strongly nuclear in
these NIH 3T3-derived cells, similar to the corrected con-
trol subline H35 before or after temperature shift and sim-
ilar to endogenous Pten localization in mouse embryonic
fibroblasts (MEFs, Figure 6B). But already 18 hr after the
temperature shift, Pten started to accumulate in the cyto-
plasm, leading to a strong cytoplasmic stain by 36 and 60
hr, consistent with an import defect of newly synthesized
Pten. As expected, the cells also revealed an aberrant
Ub-localization pattern at 36 and 60 hr (Figure 6A, right).
To test whether the Ub-mediated PTEN transport was
indeed due to direct ubiquitination of PTEN, we studied
the role of the PTEN-targeting E3 ligase, NEDD4-1, in
PTEN localization. Transient transfection of MEF cells with
control siRNA showed dominant nuclear Pten and strong
cytoplasmic Nedd4-1 localization (Figure 6B). Nedd4-1
knockdown, in contrast, led to a redistribution of Pten
into the cytoplasm. Thus, we were able to phenocopy
the effect of E1 ligase deficiency on PTEN localization by
disruption of Nedd4-1. Importantly, Nedd4-1 mediated
Pten import in addition to Pten degradation (see Figure 6C
and Discussion). Similarly, knockdown of NEDD4-1 led
to a cytoplasmic and perinuclear accumulation of exoge-
nous PTEN in HeLa cells, while co-overexpression with
GFP-PTEN resulted in strong nuclear PTEN (Figure 6D).
Because NEDD4-1 in addition to PTEN polyubiquitination
also mediates its monoubiquitination in vitro and in vivo
(Wang et al., 2007), we conclude that PTENmonoubiquiti-
nation at discrete lysines, including K13 and K289, directly
regulates its import and shuttling. Consequently, the small
pool of discretely shifted monoubiquitinated PTEN shown
in Figures 4A–4C represents the steady-state PTEN frac-
tion that is shuttling competent.
Polyubiquitination, in contrast, resulted in cytoplasmic
PTEN retention: the GFP-PTEN-Ub-KØ mutant, which
was characterized by strong polyubiquitination in SDS-
PAGE analysis (Figures 4D and 4E), showed import
defects when assayed by FRAP and cytoplasmic accumu-
lation in IF (Figure 6E). To determine nucleocytoplasmic
distribution of the clearly visible ubiquitinated forms of
this fusion, nuclear and cytoplasmic fractions of these
cells were analyzed by western blotting. As expected(Figure 6F), polyubiquitinated PTEN adducts were exclu-
sively cytoplasmic while the GFP-PTEN-Ub-KØ fusion
itself displayed a distribution similar to GFP-PTEN. In con-
trast, the monoubiquitinated form, which largely depends
on K13 and K289 availability (see Figure 4E), was specifi-
cally enriched in the nuclear fraction (10-fold compared to
nonmodified PTEN, see quantification in Figure S1G), con-
firming that monoubiquitinated PTEN is shuttling most
efficiently. Notably, these results also suggested that the
pseudoubiquitination, which fuses Ub in frame to PTEN
(GFP-PTEN-Ub-KØ), does not increase PTEN shuttling
and thus cannot mimic the effect of ubiquitination on the
true target sites.
Nuclear PTEN Is Stable, Active, and Rarely Found
in Late-Stage Colon Cancer
We next sought to determine why loss of nuclear PTEN
localization could be oncogenic. To this end, we first de-
termined PTEN half-life after forced localization to the nu-
clear or cytoplasmic compartment using PTEN-NLSSV-40
or PTEN-NESPKI (see Figure S1A, lowest panels). While
WT PTEN, which as demonstrated above is both nuclear
and cytoplasmic, showed a half-life of roughly 7.5 hr
(Figure 7A), forced cytoplasmic accumulation led to a
clear decrease in stability (t1/2 = 4.5 hr), while nuclear
localization resulted in increased stability (t1/2 = 15 hr) as
predicted because NEDD4-1 is mostly cytoplasmic (see
Figures 5B, 6B, and 6D). To test nuclear PTEN activity,
we next measured its ability to antagonize AKT. As shown
(Figure 7B), transfection of increasing amounts of PTEN
into PTEN-deficient PC3 cells resulted in 75% reduction
(compared to the control) in the phospho-AKT:AKT ratio.
But surprisingly, forced nuclear PTEN was still able to
antagonize AKT activation, similar to forced cytoplasmic
(unstable) PTEN.
Next, we tested whether nuclear PTEN was also able to
induce apoptosis. After transfection of PC3 cells, cleaved
caspase-3 staining was performed and positive cells were
counted. PTEN-NES transfection into these p53-deficient
cells resulted in an apoptotic index of 4.4 (±1.7) positive
cells per 1000 (at 48 hr), while nuclear PTEN was as effi-
cient with 4.8 positive cells (±1.3 per 1000), similar to
PTEN transfection (3.1 ± 1.0 per 1000) and in contrast to
vector transfection (0.4 ± 0.0 per 1000). In sum, our data
showed that nuclear PTEN is more stable, can inhibit
AKT, and is able to induce p53-independent apoptosis.
Finally, to test the general relevance of nuclear PTEN in
the colon, we analyzed a tumor tissue microarray (TTM)Figure 6. NEDD4-1 Dictates PTEN Localization in Murine and Human Cells
(A) Endogenous Pten shows an import defect in ts20 cells after shift to the restrictive temperature for times indicated. Scale bars, 10 mm.
(B) Endogenous Pten shows cytoplasmic accumulation after knockdown of Nedd4-1 in MEF cells. Scale bars, 10 mm.
(C) Nedd4-1 siRNA efficiently reduces Nedd4-1 levels, resulting in a Pten increase in MEFs.
(D) NEDD4-1 siRNA and overexpression also dictate localization of overexpressed GFP-PTEN in HeLa cells. Arrows point at cell nuclei. Note
perinuclear PTEN accumulation upon NEDD4-1 knockdown. Scale bars, 10 mm.
(E) FRAP measurement of GFP-PTEN-Ub fusion reveals import defect of polyubiquitinated PTEN and its dominant cytoplasmic localization by IF
(insert). Error bars show SD. Scale bar, 10 mm.
(F) Fractionation and western analysis of GFP-PTEN and its fusion to Ub (GFP-PTEN-Ub-KØ). Note that the monoubiquitination band is the dominant
form of PTEN that is specifically enriched in the nuclear fraction (+ mono-Ub).Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc. 151
Figure 7. Nuclear PTEN Is Stable and Active In Vivo and Reduced in Late-Stage Colon Carcinoma
(A) Half-life of PTEN after forced nuclear (-NLS) or cytoplasmic (-NES) overexpression compared to WT PTEN in presence of cycloheximide (CHX).
Densitometry quantification (PTEN: actin, upper panels) and raw data (lower panels) are shown. Control transfection is indicated (vec).
(B) Titration of nuclear versus cytoplasmic PTEN activity. Quantification of pAKT:AKT ratio and PTEN expression levels (inserts). ‘‘v’’ indicates vector
control transfection. PTEN levels are shown, and AKT is used as loading reference.
(C) PTEN localization in TTMwith specimens of 87 colon cancer patients reveals positive correlation between nuclear PTEN localization and low tumor
grade. Statistical significance is indicated (p, see also Experimental Procedures).152 Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc.
with specimens of 87 colon cancer patients for tumor
grade and PTEN localization (PTEN-negative samples
were significantly associated with advanced tumor stage,
p < 0.022, and were omitted for this analysis). As summa-
rized in Figure 7C, we found that samples with high nu-
clear PTEN staining significantly associated with less ad-
vanced pathological stage. In addition, an increase in
even nucleocytoplasmic PTEN distribution was associ-
ated with higher tumor stage, consistent with previous
findings (Zhou et al., 2002). Taken together, these data
were in agreement with the notion that tumors that can re-
tain a strong nuclear PTEN staining remain of lower grade.
DISCUSSION
The molecular makeup of spontaneous cancers at the
clinical stage usually presents a complex mixture of pri-
mary and consequential events, some of which are
thought to contribute to essential aspects of tumor pro-
gression (Hanahan and Weinberg, 2000). Cancer syn-
drome-associated mutations, in contrast, often constitute
well-defined primary tumorigenic events that are causal to
tumor formation (Nagy et al., 2004). Specifically, germline
mutation of PTEN has been shown to underlie the closely
related autosomal dominant tumor susceptibility syn-
dromes Cowden disease and Bannayan-Riley-Ruvalcaba
syndrome (Eng, 2003). Therefore, we anticipated that
PTEN germline mutations would hold valuable information
and novel insights into PTEN function in tumor initiation.
While most of the describedmutations result in truncation,
many PTEN missense mutations affect its catalytic activ-
ity. Through investigating instead how the enzymatically
functional PTENK289E mutant could be at the root of inher-
itable cancer, we have come to several novel conclusions:
(1) We have discovered that deficiency in PTEN import
causes cancer susceptibility, independent of cata-
lytic activity. While it has been previously shown
that the PTENK289E mutant retains catalytic activity
(Georgescu et al., 2000), its nuclear import defect
has so far remained elusive. Correlation of the
K289E import defect with the observed cytoplas-
mic accumulation in the relevant Cowden patient
tissue thus represents to our knowledge the first
example of a causal relation between PTEN locali-
zation and cancer initiation. Since no such certainty
on the cause-and-effect relation exists in sporadic
mutations like PTENK13E (which, as published,
also suffers reduction in catalytic activity [Walker
et al., 2004]), the K289E mutation allows us to un-
ambiguously ascribe a tumor-suppressive function
to PTEN nuclear localization. In agreement with this
finding, we find significant correlation between lowtumor stage in colon cancer and dominant nuclear
PTEN localization.
(2) We show that nuclear PTEN import is regulated by
monoubiquitination, which to our knowledge repre-
sents the first example of target protein ubiquitina-
tion enhancing nuclear import (and shuttling).
PTENpolyubiquitination, in contrast, leads to its cy-
toplasmic retention and degradation (Ciechanover,
2005) and is therefore oncogenic in nature (see also
Wang et al. [2007]). Thus, PTENmonoubiquitination
and subsequent nuclear import has a protective
function, a highly relevant finding for the discussion
of NEDD4-1 in tumorigenesis (see below). As men-
tioned, Ub charging of some E2 ligases has been
shown to regulate their nuclear import (Plafker
et al., 2004), and, intriguingly, deubiquitination of
the Bcl-3 transcription factor has been recently
shown to cause its cytoplasmic accumulation (Mas-
soumi et al., 2006). Yet Bcl-3 cytoplasmic accumu-
lation due to loss of nuclear (Ub-mediated) retention
cannot be excluded, in contrast to PTEN, where
ubiquitination dictates the actual transport rates.
Monoubiquitination has previously been implied in
p53 nuclear export (Li et al., 2003; Lohrum et al.,
2001), but p53 also contains severalwell-character-
ized NLS and NES sequences that enhance trans-
port (Michael and Oren, 2003). PTEN, in contrast,
may rely entirely on the ubiquitination system for
shuttling, since no transferable NLS-like sequences
have been demonstrated for it and we have shown
that the K13 cluster does not rely on charge for im-
port. It will be interesting to see whether PTEN
shares ubiquitination-specific import receptors
with the above-mentioned cargoes.
(3) We identify K13 and K289 as two major and con-
served sites for PTEN ubiquitination, and we
show that their mutation leads to a constitutive
shuttling defect that can be overcome by forced
monoubiquitination. Importantly, PIP2 phospho-
lipid binding and allosteric PTEN activation func-
tions have also been ascribed to the basic patch
containing K13 (for a review see Leslie and Downes
[2004]), and it will be interesting to see how these
functions affect ubiquitination and vice versa.
Since further sites on PTEN can also be ubiquiti-
nated both in vitro and in vivo, we hypothesize
that monoubiquitination efficiency is a limiting
step of PTEN shuttling, and that Ub proteases re-
verse this process and antagonize shuttling be-
cause the nuclear pool of PTEN is not quantitatively
monoubiquitinated. Taken together, our data sug-
gest a model (Figure 7D) in which cytoplasmic
monoubiquitination of PTEN leads to either PTEN(D) Model for regulation of PTEN import and shuttling versus PTEN degradation. PTEN is ubiquitinated in the cytoplasm by NEDD4-1, which allows for
PTEN import. Alternatively, PTEN is ubiquitinated further in the cytoplasm and degraded by the proteasome. Nuclear PTEN can shuttle back to the
cytoplasm or, after deubiquitination, remain nuclear and protected from cytoplasmic degradation. Importantly, nuclear PTEN is not only protected but
is still able to antagonize AKT and cause apoptosis. Thus, PTEN-specific Ub ligases and proteases regulate PTEN localization, function, and stability.Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc. 153
import or, alternatively, polyubiquitination and
PTEN degradation (by NEDD4-1). Nuclear PTEN-
Ub can shuttle back to the cytoplasm or, after deu-
biquitination, remain nuclear and protected from
cytoplasmic degradation until it is again monoubi-
quitinated and exported.
(4) We demonstrate that PTEN nuclear localization is
coupled to activity of the only known PTEN E3 li-
gase, NEDD4-1, which can both mono- and polyu-
biquitinate PTEN in vitro and in vivo. Because we
here show that monoubiquitination is essential for
PTEN function, NEDD4-1 effectively has both onco-
genic (PTEN degradation) and tumor-suppressive
(PTEN shuttling) potential. Several scenarios of
how PTEN levels and localization are regulated
can therefore be envisioned: first, NEDD4-1 modifi-
cation/protein association could switch it from
mono-topolyubiquitinationmode;second,NEDD4-1
localization could dictate PTEN levels in a particular
compartment (in polyubiquitination mode) and/or
transportoutof thecompartment (inmonoubiquitina-
tionmode). In this respect, it is interesting to note that
although many cells show dominant cytoplasmic
NEDD4-1, some cell lines and certain murine tissues
show strong nuclear NEDD4-1 (L.C.T. and P.P.P.,
unpublished data). Significantly, the above implica-
tions for NEDD4-1 localization and activity apply
equally to PTEN deubiquitinases, which we propose
to be essential for control of PTEN residence times
andstabilitywithin thenuclear andcytoplasmiccom-
partments as depicted (Figure 7D).
(5) We find that nuclear PTEN is not only protected but
is still able to antagonize AKT and cause apoptosis.
These findings are in line with our observation of
dominant nuclear PTEN localization in early-stage,
but not advanced-stage, colon cancer. Together
with our observations in the Cowden patient tissue,
these data suggest that retention of the nuclear im-
port capability of PTEN is a critical tumor-suppres-
sive determinant, and it will be interesting to see
whether other patient-derived PTEN mutations
also target PTEN import instead of catalytic activity.
Taken together, we have, through an integrative ap-
proach, linked the genetics of a cancer syndrome
with the biochemistry and cell biology of protein
modification to demonstrate how ubiquitination
regulates nuclear import and tumor progression
through PTEN. We therefore propose that Ub is
a decisive regulator of this major tumor suppressor
and that further defining this process is crucial to
understanding and developing ubiquitination-re-
lated cancer therapies.
EXPERIMENTAL PROCEDURES
Plasmids and Protein Purification
PTEN cloned into pcDNA3.1 (Lee et al., 1999) was subcloned into
pEGFP-C2 and its derivatives constructed as described in the Supple-154 Cell 128, 141–156, January 12, 2007 ª2007 Elsevier Inc.mental Data section. The WT Ub plasmid contains eight tandems of
HA-Ub under the CMV promotor. For protein production, PTEN,
PTENK289E, and PTENRKR were expressed via baculovirus as detailed
in the Supplemental Data.
In Vitro Ubiquitination Assays
Monoubiquitination reactions of WT PTEN and K289E mutant were
carried out at 30C for 2 hr in 40 mM Tris-HCl (pH 7.5), 2 mM DTT,
and 5 mMMgCl2, using 10 mg of KØ-Ub mutant (Boston Biochem, cat-
alog number UM-NOK), 40 nM human E1 (Boston Biochem, catalog
number E302), 8 mM UbCH5c, 5 mM ATP (Sigma, catalog number A-
7699), 300 ng of recombinant PTEN or GST-PTEN-RKR, and 2 ml puri-
fied NEDD4-1 (see Wang et al. [2007]). See Supplemental Data for de-
tailed information.
Cells, Western Blotting, and Immunocytochemistry
For IF, cells were prepared using standard preparation and confocal
analysis procedures detailed in Supplemental Data. The ts20 cell line
was a kind gift from Dr. H. Ozer (New Jersey Medical School).
Nedd4-1 knockdown was performed in Trp53/ MEFs using the
pSuper-Retra-LacZ (LacZi) or pSuper-Retra-Nedd4-1 (iN4A) plasmids
(see Wang et al. [2007] and Supplemental Data). For protein half-life,
cells were treated with 30 mg/ml cycloheximide as previously de-
scribed (Chen et al., 2005). Half-life extrapolation, nucleocytoplasmic
fractionation, apoptosis assays, and IPs were carried out using the
standard methods described in the Supplemental Data section.
Photobleaching In Vivo Import/Export Assays
PC3 cells were plated, transfected with Lipofectamine 2000, and ob-
served in LabTekII chambers (Nalgene) at 24 hr posttransfection (iden-
tical results were obtained at 36 hr, data not shown). Import/export as-
says were performed on a Zeiss LSM 510 confocal microscope and
evaluated as described (see references and detailed methods in Sup-
plemental Data).
Mass Spectrometry
Gel-resolved proteins ‘‘PTEN RKR’’ (control) and ‘‘Ub-PTEN RKR’’ de-
rived from the ubiquitination reactions were digested with trypsin and
batch purified on a reversed-phase microtip, and resulting peptide
pools were individually analyzed by matrix-assisted laser desorption/
ionization reflectron time-of-flight (MALDI-reTOF) MS (UltraFlex TOF/
TOF; Bruker; Bremen, Germany) for peptide mass fingerprinting as de-
scribed in Supplemental Data.
Immunohistochemistry on Patient Samples and Tumor Tissue
Microarrays
Cowden patient colon sample slides were stained for PTEN using the
monoclonal 6H2.1 (Cascade, Figure 1D) and polyclonal Ab-2 (Nem-
oarkers) as previously described (Trotman et al., 2003). Tissue micro-
array construction, its staining, and scoring methods are detailed in
Supplemental Data.
Statistical Analysis, Sequence Alignments, and PTEN Modeling
Statistical significance calculations, PTEN sequence alignments, and
modeling are described in the Supplemental Data section.
Supplemental Data
Supplemental Data include one figure, Supplemental Experimental
Procedures, and Supplemental References and can be found with
this article online at http://www.cell.com/cgi/content/full/128/1/141/
DC1/.
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